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ABSTRACT 
A simple reversed-phase high-performance liquid chromatographic (RP-HPLC) method has been 
developed and validated of rosiglitazone in bulk and tablet dosage form. Chromatographic analysis 
was performed on a C18 column (250x 4.6 mm, 5µm) with a mixture of Ammonium dihydrogen 
phosphate buffer (pH 4.5): Acetonitrilein the ratio 65:35 as mobile phase, at a flow rate of 1.0 mL 
min−1. UV detection was performed at 230 nm. The method was validated for accuracy, precision, 
specificity, linearity, and sensitivity. The retention times of rosiglitazone was found to be 7.19±0.145 
respectively. Linearity was obsered in concentration ranges of 12–70 µg mL−1. The limit of detection 
was 0.725 and the quantification limit was 2.41 µg/ml. The accuracy of the proposed method was 
determined by recovery studies and found to be 98.26% to 101.37%. Commercial tablet formulation 
was successfully analyzed using the developed method and the proposed method is applicable to 
routine analysis of determination of rosiglitazone and in bulk and tablet dosage form. 
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1. Introduction 
Rosiglitazone is a thiazolidinedione derivative 
and it is used for the treatment of type 2 
diabetes mellitus, chemically it is 5-[[4-[2-(5-
ethylpyridin-2-yl) ethoxy] phenyl] methyl]-1, 
3-thiazolidine-2, 4-Dione. Rosiglitazone is an 
oral antidiabetic agent and acts as an agonist 
at PPAR gamma receptors have acts primarily 
enhances tissue sensitivity to insulin.  A 
literature survey reveals that various 
analytical methods like rosiglitazone by 
HPLC and MECK2, Simple HPLC method for 
the determination of rosiglitazone in human 
plasma 3,4, Simultaneous HPLC estimation of  
metformin in combination with  rosiglitazone5 
,rosiglitazone  with  gliclazide in tablet6, 
rosiglitazone and gemfibrozil in human 
plasma 7. Simultaneous LC-UV estimation of 
rosigliazone and glimepiride in plasma8, 
rosigliazone and glimepiride in human 
plasma9. Simultaneous LC-ESI-MS method 
for estimation of rosigliazone and N-
desmethyl rosiglitazone in human plasma10. 
But these methods are sophisticated, 
expensive and time consuming when 
compared to simple HPLC method. There is 
need for a interest to develop simple, 
accurate, specific, sensitive, precise and 
reproducible HPLC method for the estimation 
of rosiglitazone in bulk and its formulation.  
Fig.: Chemical structure of Rosiglitazone 
 
2. Experimental 
2.1. Materials and Methods: Pure standard 
of rosiglitazone (Assigned purity 99.98%) 
was obtained as a gift sample from Micro 
labs Pvt. Ltd, Badi, India. The gift samples 
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were used as standard without further 
purification. HPLC grade water, methanol 
(Qualigens), ammonium dihydrogen 
phosphate, glacial acetic acid and ammonia 
(S.D. fine chemicals, Mumbai, India), were 
used throughout the experiment. Commercial 
pharmaceutical preparation (Avandia) which 
was claimed to contain 4mg of rosiglitazone 
is used in analysis. The chemical structure 
and purity of the sample obtained was 
confirmed by TLC, IR, Melting point studies.  
2.2. Instrumentation and chromatographic 
conditions: High performance liquid 
chromatography, Shimadzu pump LC-10AT 
VP     equipped with universal injector 
(Hamilton 25 µL) SPD10A, UV-VIS detector 
SPD10A-10A VP (Shimadzu) was used. 
Isocratic elution of mobile phase comprising 
of Ammonium dihydrogen phosphate buffer 
65% (pH 4.5)  Acetonitrile 35% (pH 4.5) flow 
rate of 1.0 ml min-1 was performed on C18 
column (250x 4.6 mm, 5µm). The effluent 
was detected at 230 nm. The  retention times 
of  rosiglitazone  were 7.19±0.145min. The 
column temperature was maintained at 
ambient and the volume of injection was 20 
µl. Prior to injection of analyte, the column 
was equilibrated for 30- 40 min with mobile 
phase.  
2.3. Preparation of mobile phase: The HPLC 
grade solvents were used for the preparation 
of mobile phase, isocratic elution of mobile 
phase comprising of of Ammonium 
dihydrogen phosphate buffer 65% (pH 4.5)  
Acetonitrile 35% [(Solvent A), Ammonium 
dihydrogen Phosphate Buffer: Dissolve 2.003 
gm of ammonium dihydrogen phosphate (0.02 
M) in 1000 ml of water, adjust the pH to 4.5 
with ammonia or glacial acetic  acid, (solvent 
B)   Acetonitrile]. The contents of the mobile 
phase were mixed in the ratio of ammonium 
dihydrogen phosphate buffer: acetonitrile 
(65:35) and phase were filtered before use 
through a 0.45µm membrane filter, sonicated 
and pumped from the solvent reservoir to the 
column at a flow rate of 1 ml/min. 
2.4. Standard solution: Standard stock 
solutions 1 mg mL-1 of rosiglitazone was 
prepared in methanol and further diluted in 
mobile phase. The working standard solutions 
were prepared in mobile phase to contain 
mixture of rosiglitazone in over the linearity 
range from 20 –70 µg/ml. 
2.5. Assay in formulation: Twenty tablets 
each containing and their average weight was 
calculated. The tablet  were crushed to furnish 
a homogenious powder and a quantity 
equivalent to one tablet  were weighed in to a 
100 ml volumetric flask, dissolve in methanol, 
sonicated for about 15 min and then made up 
to volume with mobile phase. The solution 
was stirred for 10 min using a magnetic stirrer 
and filtered into a 100 ml volumetric flask 
through 0.45 µm membrane filter. The residue 
was washed 3 times with 10 ml of mobile 
phase, and then the volume was completed to 
100 ml with the same solvent. Further add 
mobile phase to obtain an expected 
concentration of 10µg/ml. All determinations 
were conducted in triplicate. 
 
3. Results and Discussions 
The proposed HPLC method required fewer 
reagents and materials and it is simple and 
less time consuming. This method could be 
used in quality control test in pharmaceutical 
industries. The chromatograms of 
rosiglitazone are shown in (Fig No.1). There 
was clear resolution between rosiglitazone 
with retention time of 7.19±0.145 minutes 
respectively.  
3.1. Linearity: Linearity was observed in 
concentration ranges of 12–70 µg/ mL. The 
response was determined to be linear over the 
range of 20µg/ml to 70µg/ml (20, 30, 40, 50, 
60, and 70). The solutions were injected into 
HPLC system. Each of the concentration was 
injected in triplicate to get reproduciable 
response. The run time was 13 min and the 
peak areas were measured. The calibration 
curve was plotted as concentration of the 
respective drug versus the response at each 
level. The purposed method was evaluated by 
its correlation coefficient and intercept value 
calculated by statistical study. They were 
represented by the linear regression equation. 
(Fig 2& 3 calibration curve) 
YRosiglitazone = 511985x + 1060943      
Coefficient of correlation (r2) value = 0.9998 
3.2.  Accuracy: The accuracy is the closeness 
of the measured value to the true value for the 
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sample. Accuracy was found out by recovery 
study from prepared solution (three replicates) 
with standard solution, of the label claim. 
Aliquots of 1 ml, 3ml and 5 ml of sample 
drug from rosiglitazone solution of 100µg/ml 
were pipetted into each of three volumetric 
flasks. To this 1 ml of standard drug solution 
of 100µg/ml was added to each volumetric 
flask respectively. The volume was made up 
to 10 ml with mobile phase. 20 µl of each 
solution was injected and chromatograms 
were recorded. The range was found between 
98.26 to 101.37 % respectively. The values of 
recovery justify the accuracy of the method. 
The % recovery values were obtained within 
the standard limit which confirms that the 
method is accurate and free from any positive 
or negative interference of the excipients. 
(Table No.2)    
3.3. Limit of detection and quantification: 
Limit of detection is determined by the 
analysis of samples with known 
concentrations of analyte and by establishing 
the minimum level at which the analyte can 
be reliably detected. 
The detection limit (LOD) and quantitation 
limit (LOQ) may be expressed as: 
 L.O.D. = 3.3(SD/S)          Where, SD = 
Standard deviation of the response 
  L.O.Q. = 10(SD/S)                S = Slope of the 
calibration curve                         
The slope S may be estimated from the 
calibration curve of the analyte.  
The LOD was found to be 0.725 µg/ml  and 
LOQ was found to be 2.41 µg/ml and for 
rosiglitazone respectively which represents 
that sensitivity of the method is high. 
3.4 Precision: Repeatability involves analysis 
of replicates by the analyst using the same 
equipment and method and conducting the 
precision study over short period of time 
while reproducibility involves precision study 
at different occasions, different laboratories, 
and different batch of reagent, different 
analysts, and different equipments.  The 
repeatability study which was conducted on 
the solution having the concentration of about 
40 µg/ml for rosiglitazone (n =6) showed a 
RSD of 0.337% for rosiglitazone. It was 
concluded that the analytical technique 
showed good repeatability. (Table No.3) 
3.5. Reproducibility and Ruggedness: The 
ruggedness of an analytical method is 
determined by analysis of aliquots from 
homogenous lots by different analysts using 
operational and environmental conditions that 
may differ but are still within the specified 
parameters of the assay. The assay was 
performed in different condition, different 
analyst, and different dates. (Table N0.4) 
3.6. Robustness: The robustness of the 
method was determined by delibrate changes 
in the method like alteration in pH of the 
mobile phase, percentage organic content, 
changes in the wavelength. The robustness of 
the method shows that there were no marked 
changes in the chromatographic parameters, 
which demonstrates that the method 
developed is robust.  
3.7. Specificity: The selectivity of an 
analytical method is its ability to measure 
accurately and specifically the analyte of 
interest in the presence of components that 
may be expected to be present in the sample 
matrix. If an analytical procedure is able to 
separate and resolve the various components 
of a mixture and detect the analyte 
qualitatively the method is called selective. 
It has been observed that there are no peaks of 
diluents and placebo at main peak’s. Hence, 
the chromatographic system used for the 
estimation of rosiglitazone is very selective 
and specific .Specificity studies indicating 
that the excipients did not interfere with the 
analysis. For demonstrating the specificity of 
the method for drug formulation the drug was 
spiked and the representative chromatogram 
(Fig No.4) 
3.8. System Suitability: A binary solution of 
70 µg mL-1of rosiglitazone (in triplicate) was 
prepared and same was injected, then the 
system suitability parameters were calculated 
from the following chromatogram. (Table 
No. 5)  
 
Conclusion 
The proposed RP-HPLC method is found to 
be simple, accurate, precise, linear, and 
specific, and, for quantitative estimation of 
rosiglitazone in bulk and its tablet 
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formulation. Therefore, the HPLC method 
described here can be used for routine 
analysis in bulk and its tablet formulation. 
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Table No.1: For Peak Area of Rosiglitazone 
Conc. In 
µg/mL 20 30 40 50 60 70 
Replicate    1 11210714 16437253 21543371 26617388 31692012 36967508 
Replicate    2 11228134 16527580 21642513 26518298 31256978 37025146 
Replicate    3 11202714 16655058 21607365 26845881 31741253 37085964 
Avg 11213854 16539964 21597750 26660522 31563414 37026206 
SD 12997.65 109429.3 50265.55 167997.3 266521.3 59235.11 
RSD 0.115907 0.661605 0.232735 0.630135 0.844399 0.159982 
 
Table No.2 Result of recovery studies 
S.No Conc. taken in (µg/ml) 
Std addition  in 
(µg/ml)
Total Conc. found 
in (µg/ml)* 
% recover 
1 10 10 20.27 101.373±1.519 
2 10 30 39.308 98.269±0.100 
3 10             50 60.64 101.088±0.457 
Mean ± 
SD 
100.240±1.72 
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Table No.3 Result of repeatability analysis 
S.No. Conc. 
(µg/ml) 
Peak Area 
(µV*sec) Mean ± SD % RSD 
1 
 
R
O
SI
G
LI
TA
ZO
N
E 
   
 4
0(
µg
/m
l 
21151753   
 
 
211321191 
±71311.03 
 
 
 
 
0.337452 
2 
 21245204 
3 
 21092287 
4 
 21031368 
5 
 21120761 
6 
 21151773 
Table No.4 Results of reproducibility 
Parameter Result observed 
ROSI 
Average Percentage Recovery 99.20% 
SD between set of analysis on same date 0.432 
SD between set of analysis on different date 1.06 
RSD between set of analysis on same date 0.442% 
RSD between set of analysis on different date 1.06% 
 
Table No 5. Results of system suitability parameters 
 
Parameters Data obtained 
ROSI 
Number of theortical plates 4153 
Symmetry factor/ Tailing factor 1.21 
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Fig No. 1.Typical  chromatogram  showing  rosiglitazone 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Calibration curve for Rosiglitazone 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure No.3.Chromatogram showing Specificity 
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